The Treatment Of Idiopathic Pulmonary Fibrosis About Anti-fiber Particles And Its Effects On T Lymphocyte Subpopulation

Objective:The topic under the guidance of TCM theory, clinical and laboratory instructors inthe past based on the research, study pulmonary fibrosis pathogenesis, Qi and Yin with atoxin, the role of Huatan Tongluo Kangxian particle treatment of pulmonary fibrosis. Aftertreatment of patients by improving the degree of symptoms and signs, on lung function, lungcompliance, blood gas analysis, CT of the chest and changes of T lymphocyte subpopulationlevels before and after treatment the changes in. Reveal the mechanism of effect of Chinesemedicine, for the objective study of Chinese medicine and the future of Chinese medicinetreatment of pulmonary fibrosis drug laws seek to lay the groundwork for the treatment ofpulmonary fibrosis open up new avenues.Method:According to the order before and after admission patients were randomly dividedinto two groups: treatment group and control group,30cases each. Two groups of patientsaccording to disease and sputum culture conditions, give antibiotics, controlled oxygentherapy and other therapeutic measures. Before treatment and observation period15not touse corticosteroids. The treatment group taking anti-fiber particles, while with a small doseof prednisone, for3months; The control group was treated with prednisone, for3months.Both groups give the same nutrition therapy, avoid the use of immunosuppressive agents andTraditional Chinese medicine preparations. Addition to disease progression during treatment,death to stop observation, not free to change the treatment. Observed indicators are:①Ingeneral, symptoms and signs.②Safety indicators:Blood, urine, liver and kidney functionwill be conventional and ECG.③lung function are repeated twice each inspection,whichever is higher value.④Dyspnea score.⑤Aarterial blood gas analysis: two groups ofpatients before and after treatment with ISTAT blood gas analyzer blood gas to arterialpartial pressure of oxygen (PaO2) as the main target.⑥T lymphocyte Flow cytometry wasused to detect CD3+, CD4+and.CD8+T relative lymphocyte count In the course of theseindicators before and after treatment, the test time in order to control observation. Before andafter treatment symptoms, signs, blood gas analysis and pulmonary function, chest CT, and Tlymphocyte subpopulation changes. Data by SPSS13.0for Windows statistical software for processing, observed during the two groups before treatment showed no statistical significantdifference.Results:①Two groups were the main symptom scores after treatment were decreased todifferent extent, suggesting that the two treatments can improve clinical symptoms. Resultsshowed differences in symptom score after treatment was significantly (P＜0.05). Two mainsymptoms total score before and after treatment were significantly different (P＜0.05), twopoints after treatment were significantly different (P＜0.05),shows clinical symptoms of thetreatment group improved effective than the control group more effective than the controlgroup.②The Velcro sound before and after treatment were significantly different (P＜0.05),after treatment, there was significant difference (P＜0.05).③Difficulty breathing pointsbefore and after treatment groups were significantly different (P＜0.05), after treatment,significant difference between the two groups (P＜0.05), respiratory difficulties inimproving the efficacy of the treatment group than the control group.④After treatment, totallung capacity, vital capacity, pulmonary diffusing capacity were improved compared withbefore treatment, there was significant difference (P＜0.05), before and after the controlgroup were no significant differences (P＞0.05)⑤After treatment, patients were higherarterial partial pressure of oxygen, there was significant difference (P＜0.05).⑥Aftertreatment, chest CT in7cases improved,17cases of stable state, compared with6casesbefore treatment progress, the effective rate was80%; In the control group improved in5cases the chest CT,12patients with stable,13cases increased, the effective rate was56.7%.After treatment, no significant difference (P＞0.05).⑦A fter treatment,Comparison of twogroups of T lymphocyte subsets of statistical results, The control group after treatment CD3+,CD4+, CD8+compared with those before treatment has the difference.(p<0.05). Aftertreatment, CD3+, CD4+, CD8+than the control group after treatment with difference.(p<0.05). Effect of the treatment group was significantly.(p<0.01).⑧After treatment, totaleffective rate was84.4%,46.7%of the control group, the total efficiency of the two groupswere significantly different (P＜0.05).⑨Through two sets of blood, urine, stool, liver andkidney function and ECG observed in the treatment group and the control group had noadverse events.Conclusion:Anti-fiber particles can significantly improve symptoms and signs in patientswith pulmonary fibrosis, to improve pulmonary function and PaO2, Increase lung diffusingcapacity and improve the chest HRCT, to effectively improve the quality of life of patientsand can delay the disease’s further development. Anti-fiber particles could improve cellularimmunity and humoral immunity index, inhibit profibrotic cytokine production and expression, form against pulmonary fibrosis. Anti-fiber particles can reduce drug side effects,improve patient physique.